In the claims

a'

1. (amended) A compound of Formula I:



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

Halogen[(F, Cl, Br)],

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

a'

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-;

wherein one of R^1, R^2, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7, and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[(F, Cl, Br)], $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C$-$(CH_2)_n$-,

$R^{15}R^{16}NCO$-$(CH_2)_n$-,

NC-$(CH_2)_n$-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

–$(CH_2)_mCH_2(R^{15})NCO$-,

–$(CH_2)_mCH_2OCO$-, or

–$(CH_2)_mCH_2CH_2CO$-;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{14}HNCO$-, or

$R^{14}CONH$-;

a'

R^{12} is

H,

Halogen[(F, Cl, Br)],

HO,

$R^{13}O$-,

$R^{15}R^{16}N$-,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}CO$-, or

$R^{14}CONH$-;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H.

2. (amended) The compound of claim 1 of Formula I wherein

one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, [$R^{13}S$-] $R^{14}S$-, halogen[(F, Cl, Br)], or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-, or

$R^{15}CO$-[, or]

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

3. (amended) A composition comprising [The]the compound of claim 2 and [further comprising] a pharmaceutically acceptable carrier.

4. (amended) The [compound] composition of claim 3 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazoleproprionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a'

5. (amended) The compound of claim 2 of Formula I selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-

a'

benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-

propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

a'

6. (amended) A composition comprising [The] the compound of claim 5 [further comprising] and a pharmaceutically acceptable carrier.

7. (amended) The [compound] composition of claim 6 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

8. (amended) A composition comprising the [The] compound of claim 1 [further comprising] and a pharmaceutically acceptable carrier.

9. (amended) The [compound] composition of claim 8 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

10. (amended) A method for treating a patient having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA)

subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula I:

Q'



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

halogen[(F, Cl, Br)],

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-;

wherein one of R^1, R^2, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7, and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[(F, Cl, Br)], $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C$-$(CH_2)_n$-,

$R^{15}R^{16}NCO$-$(CH_2)_n$-,

NC-$(CH_2)_n$-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

–$(CH_2)_m CH_2(R^{15})NCO$-,

–$(CH_2)_m CH_2OCO$-, or

–$(CH_2)_m CH_2CH_2CO$–;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{14}HNCO$-, or

$R^{14}CONH$-;

a'

R^{12} is

H,

Halogen[(F, Cl, Br)],

HO,

$R^{13}O$-,

$R^{15}R^{16}N$-,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}CO$-, or

$R^{14}CONH$-;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

a'

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H,

in combination with a pharmaceutically acceptable carrier.

11. (amended) The method of claim 10 wherein, in the compound of Formula I, one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, [$R^{13}S$-] $\underline{R^{14}S}$-, halogen[(F, Cl, Br)], or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-, or

$R^{15}CO$-[, or]

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

13. (amended) The method of claim 11 wherein the compound of Formula I is selected from the group consisting of

a^2

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-

a^2

ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-

Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

16. (amended) A compound of Formula II:



wherein

R^1[, R^2, R^3] and R^4 are independently

H,

HO,

$R^{13}O$-,

Halogen[(F, Cl, Br)],

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

R^2 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when R^3 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

$-OCH_2S$-,

$-SCH_2CH_2S$-,

$-SCH_2CH_2O$-, or

$-OCH_2CH_2S$-; or

one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[(F, Cl, Br)], $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

[R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;]

R^{18} and R^{19} are independently

H,

Halogen[(F, Cl, Br)],

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$-, or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H.

17. (amended) The compound of claim 16 of Formula II wherein one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen[(F, Cl, Br)], or C1-C3-alkyl; R^2 and R^3 taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-; R^{20} and R^{21} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

18. (amended) A composition comprising the [The] compound of claim 17 [further comprising] and a pharmaceutically acceptable carrier.

19. (amended) The composition [compound] of claim 18 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a3

20. (amended) The compound of claim 17 of Formula II selected from the group consisting of

1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, [1-(4-Aminophenyl)-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine,] 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

21. (amended) A composition comprising the compound of claim 20 [further comprising] and a pharmaceutically acceptable carrier.

22. (amended) The composition [compound] of claim 21 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

23. (amended) A composition comprising the [The] compound of claim 16 [further comprising] and a pharmaceutically acceptable carrier.

24. (amended) The composition [compound] of claim 23 in a dosage form comprising a therapeutically effective amount of the compound for treating a disorder in a patient associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors.

a3

25. (amended) A method for treating a patient having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula II:



wherein

R^1[, R^2, R^3] and R^4 are independently

H,

HO,

$R^{13}O$-,

Halogen[(F, Cl, Br)],

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-,

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

$R^{14}S$-, or

$R^{15}R^{16}N$-; or

R^2 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$- and $R^{15}R^{16}N$- when R^3 is one of H, HO, $R^{13}O$-, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CO$-, $R^{14}CONH$-, $R^{14}NHCO$-, $R^{14}NHCO_2$-, $R^{14}OCONH$-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}S$-, and $R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S$-,

$-SCH_2O$-,

SYM 114
77588/3

a^3

.. $-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$; or

one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl, or

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen[(F, Cl, Br)], $R^{13}O-$, CF_3-, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

[R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;]

a3

R^{18} and R^{19} are independently

H,

Halogen[(F, Cl, Br)],

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$-, or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H,

in combination with a pharmaceutically acceptable carrier.

26. (amended) The method of claim 25 wherein, in the compound of Formula II, one of four substituents of R^1, R^2, R^3 and R^4 must be C1-C3-alkylthio or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen [(F, Cl, Br)], or C1-C3-alkyl; R^2 and R^3 taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;